Immunovant (IMVT) News

Immunovant Shareholders Back Board, Auditor and Executive Pay

TipRanksSep 4 06:30

Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says

Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward profile after its stock's recent rally, UBS said in a note email Monday.The company's recent

MT NewswiresAug 25 01:16

UBS Adjusts Immunovant Price Target to $40 From $24, Maintains Neutral Rating

Immunovant (IMVT) has an average rating of buy and mean price target of $46.77, according to analysts polled by FactSet.Price: 43.85, Change: -0.52, Percent Change: -1.17

MT NewswiresAug 24 22:09

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Immunovant (NASDAQ:IMVT) has seen its share price rise 198% over the last year,

Simply Wall StAug 24 18:16

Top Immunovant Executive Executes Notable Insider Stock Move

TipRanksAug 22 10:03

Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biomedical ETF (03186) Captures Innovation Dividends Through Dual Allocation in Hong Kong and U.S. Markets

As of August 20, 2026, the E Fund Biopharmaceutical ETF (03186) is the only biopharmaceutical-themed ETF listed on the Hong Kong Stock Exchange that holds constituents from both the Hong Kong and U.S. biopharmaceutical sectors.

Zhitong FinanceAug 20 16:45

US Stock Market Close | US Treasury intervenes to support long-term bonds, lifting all three major indices; Moderna surges, igniting a rally in the biopharmaceutical sector, with Merck & Co up over 12% and the S&P Biotechnology ETF rising nearly 6%; Bitco

The S&P 500 closed up 0.21% at 7,707.98, the Nasdaq Composite rose 0.16% to 26,331.09, and the Dow Jones Industrial Average gained 0.22% to 53,463.05, ending a three-day losing streak for all three major indices. Moderna surged 176.97% to hit a record high, while Merck & Co jumped 13%, leading the healthcare sector's gains in the S&P; meanwhile, semiconductor and AI momentum stocks suffered heavy losses, with chip ETFs falling a cumulative 7.7% over two days.

wallstreetcnAug 20 07:02

Immunovant Earnings Call: Cash Windfall and Key Catalysts

TipRanksAug 19 08:18

Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $57

Stifel analyst Alex Thompson CFA maintains $Immunovant(IMVT.US)$ with a buy rating, and adjusts the target price from $49 to $57.According to TipRanks data, the analyst has a success rate of 73.2%

Futu NewsAug 13 10:32

J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $50

J.P. Morgan analyst Brian Cheng maintains $Immunovant(IMVT.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 54.8% and a

Futu NewsAug 10 20:31

H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $41

H.C. Wainwright analyst Douglas Tsao maintains $Immunovant(IMVT.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 56.2% and

Futu NewsAug 10 19:34

Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)

TipRanksAug 10 17:25

A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $41 to $66

On Aug 08, major Wall Street analysts update their ratings for $Immunovant(IMVT.US)$, with price targets ranging from $41 to $66.Oppenheimer analyst Leland Gershell maintains with a buy rating, and

Futu NewsAug 8 21:00

Immunovant (IMVT) Receives a Buy From Oppenheimer

TipRanksAug 7 20:46

H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $41

H.C. Wainwright analyst Douglas Tsao maintains $Immunovant(IMVT.US)$ with a buy rating, and adjusts the target price from $40 to $41.According to TipRanks data, the analyst has a success rate of 56.9%

Futu NewsAug 7 19:31

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)

TipRanksAug 7 18:50

Immunovant Fiscal Q1 Loss Widens

Immunovant (IMVT) reported a fiscal Q1 net loss Thursday of $0.75 per diluted share, compared with a loss of $0.71 a year earlier.Analysts polled by FactSet expected a loss of $0.67.Total operating

MT NewswiresAug 6 20:35

10-Q: Immunovant | 10-Q: Q1 2027 Earnings Report

SECAug 6 19:29

Express News | Immunovant, - Cash and Cash Equivalents Total $797.80 Mln as of June 30, 2026

BreakingsAug 6 19:27

Immunovant GAAP EPS of -$0.75 Misses by $0.12

Seeking AlphaAug 6 19:27